lerodalcibep

Phase 3Small molecule

LLIB Therapeutics LLC

lerodalcibep is one of 65 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypercholesterolemiaRecruiting

Efficacy and SafetyCompleted

Heterozygous Familial Hypercholesterolemia (hefh)Not yet recruiting

HypercholesterolemiaPhase 3

Recruiting

Efficacy and SafetyPhase 3

Completed

Heterozygous Familial Hypercholesterolemia (hefh)Phase 3

Not yet recruiting

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 2

Rapamune

PPrism Pharmaceuticals

Phase 3

5 3

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

3 5

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 6

Oxycontin

PPurdue Pharma LP

Phase 3

1 7

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

4 8

Avalglucosidase Alfa

Sanofi

Phase 3

1 9

Becotatug Vedotin

FFudan University

Phase 3

1 10

lerodalcibep

LLIB Therapeutics LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Not yet recruiting

Heterozygous Familial Hypercholesterolemia (hefh)

NCT07775339

Clinical

Trials by Indication[1]

Efficacy and Safety6 trials

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

Completed·LLIB Therapeutics LLC·Phase 3·NCT05004675·166 enrolled

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Completed·LLIB Therapeutics LLC·Phase 3·NCT04790513·204 enrolled

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Completed·LLIB Therapeutics LLC·Phase 3·NCT04034485·65 enrolled

Show 3 more trials

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Enrolling by invitation·LLIB Therapeutics LLC·Phase 3·NCT04798430·2,000 enrolled

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

Unknown status·LLIB Therapeutics LLC·Phase 3·NCT04797247·900 enrolled

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Unknown status·LLIB Therapeutics LLC·Phase 3·NCT04806893·900 enrolled

Tics1 trial

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

Completed·LLIB Therapeutics LLC·Phase 3·NCT05234775·22 enrolled

Hypercholesterolemia1 trial

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Recruiting·HHasten Biopharmaceutical Co., Ltd.·Phase 3·NCT06568471·210 enrolled

Familial Hypercholesterolemia1 trial

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

Completed·LLIB Therapeutics LLC·Phase 3·NCT04797104·478 enrolled

Heterozygous Familial Hypercholesterolemia (HeFH)1 trial

Open Label Phase 3b Study to Evaluate the Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia (LIBerate-Kids OLE)

Not yet recruiting·LLIB Therapeutics LLC·Phase 3·NCT07775339·150 enrolled

1 more indication

Familial Hypercholesterolemia - Heterozygous1 trial

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)

Enrolling by invitation·LLIB Therapeutics LLC·Phase 3·NCT07102511·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for lerodalcibep. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lerodalcibep compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lerodalcibep. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LIB Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLIB Therapeutics LLC

lerodalcibep

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Efficacy and Safety6 trials

Tics1 trial

Hypercholesterolemia1 trial

Familial Hypercholesterolemia1 trial

Heterozygous Familial Hypercholesterolemia (HeFH)1 trial

Familial Hypercholesterolemia - Heterozygous1 trial

References

Drug Info

Quick Facts

Related News